RBC Capital lowered the firm’s price target on Moderna (MRNA) to $28 from $32 and keeps a Sector Perform rating on the shares. The company reported a Q1 modest miss for both COVID and RSV while reiterating both revenue and cost guide for this year, the analyst tells investors in a research note. Beyond 2025, Moderna announced $1.4B-$1.7B of cost reductions by 2027 and reiterated its goal to break even by 2028, RBC adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Moderna price target lowered to $40 from $45 at Barclays
- Moderna’s Q1 2025: Revenue Decline and Strategic Focus
- Moderna’s Earnings Call: Progress Amid Challenges
- Moderna price target lowered to $28 from $32 at RBC Capital
- Moderna’s Strategic Shift Amidst Financial Challenges and Market Uncertainties: Analyst Maintains Hold Rating with Adjusted Target Price